A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 29 Jul 2016 Status changed from active, no longer recruiting to completed.
- 23 May 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2013 Planned end date changed from 1 Dec 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.